8-K - Acumen Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On July 15, 2025, Acumen Pharmaceuticals, Inc. (“ Acumen ” or the “ Company ”) entered into a strategic collaboratio

Material Agreement

$9.3M$40.0M$515.0M$555.0M

7.01

of this Report (including Exhibit 99.1), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject

Regulation Fd

9.01

Financial Statements and Exhibits. (d). Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated July 15, 2025 104 Cover Page Interactive Data File (

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1